Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 6-month, randomized, double-blind, placebo-controlled, multicenter, safety, tolerability, and efficacy study of 3 doses of lecozotan (SRA-333) SR in outpatients with mild to moderate Alzheimer's disease treated with a cholinesterase inhibitor

Next Previous
X
Search
Trial Profile

A 6-month, randomized, double-blind, placebo-controlled, multicenter, safety, tolerability, and efficacy study of 3 doses of lecozotan (SRA-333) SR in outpatients with mild to moderate Alzheimer's disease treated with a cholinesterase inhibitor

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 21 Jan 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lecozotan (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use

    • Most Recent Events

    • 19 Jul 2012 Results presented in combination with results from the 201 study at the 2012 International Conference on Alzheimer's Disease.
    • 19 Jul 2012 Patient numbers changed to 340 as reported in the conference abstract
    • 22 Jun 2012 Planned patient number of the extension trial (EudraCT2005-001478-28) is 200 as reported by European Clinical Trials Database

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top